stockrowBristol Myers Squibb Company
BMY Healthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- +6.93%
- EPS
- −2.02%
- Free cash flow
- −36.0%
- Total debt
- −12.5%
Quarter to September 2026, against a year earlier
Follow BMY
Alert me
Bristol Myers Squibb Company (BMY) Revenue
Bristol Myers Squibb Company's revenue for fiscal 2025 was $48.2B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $50.0B. Over the past ten years it has ranged from $16.6B (fiscal 2015) to $48.3B (fiscal 2024); the current reading is higher than 91% of that period. Bristol Myers Squibb Company ranks 10th of 18 Drug Manufacturers General companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $48.2B | (0.22%) |
| FY2024 | $48.3B | 7.32% |
| FY2023 | $45.0B | (2.50%) |
| FY2022 | $46.2B | (0.49%) |
| FY2021 | $46.4B | 9.09% |
| FY2020 | $42.5B | 62.62% |
| FY2019 | $26.1B | 15.89% |
| FY2018 | $22.6B | 8.59% |
| FY2017 | $20.8B | 6.94% |
| FY2016 | $19.4B | 17.31% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $13.1B | 0.74% |
| Jun 2026 | $13.0B | 12.92% |
| Mar 2026 | $11.5B | (8.10%) |
| Dec 2025 | $12.5B | 2.29% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| PFE Pfizer Inc. compare | $63.6B |
| AZN AstraZeneca PLC compare | $62.4B |
| SNY Sanofi compare | $59.1B |
| NVS Novartis AG compare | $57.4B |
| NVO Novo Nordisk A/S compare | $51.5B |
| BMY Bristol Myers Squibb Company | $50.0B |
| GSK GSK PLC Sponsored ADR compare | $44.9B |
| AMGN Amgen Inc. compare | $38.9B |
| GILD Gilead Sciences, Inc. compare | $31.0B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on BMY
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement